Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma

Nathan H Fowler, MD, Ranjana H Advani, MD, Jeff Sharman, MD, Sonali M. Smith, MD, Jesse McGreivy, MD, Lori Kunkel, MD, Vina Troung, Cathy Zhou, Thomas E. Boyd, MD

Blood (2012) 120 (21): 156.

https://doi.org/10.1182/blood.V120.21.156.156

Published: 2012

Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study

John C. Byrd, MD, Richard R. Furman, MD, Steven Coutre, MD, Ian W. Flinn, MD, PhD, Jan A. Burger, MD, PhD, Kristie A. Blum, MD, Jeff Sharman, MD, Barbara Grant, MD, Jeffrey A. Jones, MD, MPH, William G. Wierda, MD, Ph.D., Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Anh Tran, Fong Clow, ScD, Lori Kunkel, MD, Danelle F. James, M.D, Susan O'Brien, MD

Blood (2012) 120 (21): 189.

https://doi.org/10.1182/blood.V120.21.189.189

Published: 2012

Journal Articles

Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up

Michael Wang, M.D., Simon A. Rule, MD, Peter Martin, MD, Andre Goy, MD, Rebecca Auer, MD, Brad S. Kahl, M.D., Wojciech Jurczak, Ranjana H. Advani, MD, Jorge Enrique E Romaguera, MD, Jesse McGreivy, MD, Fong Clow, ScD, Michelle Stevens-Brogan, Lori Kunkel, MD, Kristie A. Blum, MD

Blood (2012) 120 (21): 904.

https://doi.org/10.1182/blood.V120.21.904.904

Published: 2012

Journal Articles

Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study

Blood (2011) 118 (21): 1875.

https://doi.org/10.1182/blood.V118.21.1875.1875

Published: 2011

Journal Articles

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Blood (2011) 118 (21): 813.

https://doi.org/10.1182/blood.V118.21.813.813

Published: 2011

Journal Articles

A Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma: Updated Efficacy and Tolerability From the Completed 20/56mg/m 2 Expansion Cohort of PX-171-007

Kyriakos P Papadopoulos, MD, Peter Lee, MD, PhD, Seema Singhal, MD, Joseph R. Holahan, MD, David H. Vesole, MD, PhD, Steven T. Rosen, MD, FRCPA, Lori Kunkel, MD, Alison L. Hannah, MD, David S. Siegel, MD, PhD

Blood (2011) 118 (21): 2930.

https://doi.org/10.1182/blood.V118.21.2930.2930

Published: 2011

Journal Articles

Novel Protein Agonist of Thrombopoiesis Acts Via a Physiocrine Pathway Distinct From That of Thrombopoietin

Minh-Ha T Do, PhD, Wei Zhang, PhD, Kyle Chiang, PhD, Chi-Fang Wu, PhD, Chulho Park, PhD, Quansheng Zhou, MD/PhD, My-Nuong Vo, PhD, Xiang-Lei Yang, PhD, Lori Kunkel, MD, Melissa A Ashlock, MD, John D Mendlein, PhD, Rajesh Belani, MD, Alain P Vasserot, PhD, Jeffry D Watkins, PhD

Blood (2011) 118 (21): 2376.

https://doi.org/10.1182/blood.V118.21.2376.2376

Published: 2011

Journal Articles

Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).

Luhua Wang, MD, David Siegel, Jonathan L. Kaufman, MD, A. Keith Stewart, MD, Andrzej J Jakubowiak, MD, PhD, Melissa Alsina, MD, Vishal Kukreti, MD, FRCPC, Nizar J Bahlis, MD, Kevin T. McDonagh, MD, Andrew Belch, MD, Michael Sebag, MD, PhD, Nashat Gabrail, MD, Mai H. Le, MD, Mark K Bennett, PhD, Lori Kunkel, MD, Michael Kauffman, MD, PhD, Robert Z Orlowski, M.D., Ph.D., Ravi Vij, MD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 302.

https://doi.org/10.1182/blood.V114.22.302.302

Published: 2009

Journal Articles

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

David Siegel, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., Jonathan L. Kaufman, MD, A. Keith Stewart, MD, Vishal Kukreti, MD, FRCPC, Melissa Alsina, MD, Andrzej J Jakubowiak, MD, PhD, Sundar Jagannath, MD, Kevin T. McDonagh, MD, Andrew Belch, MD, Nizar J Bahlis, MD, Chaim Shustik, MD, Mai H. Le, MD, Lori Kunkel, MD, Mark K Bennett, PhD, Michael Kauffman, MD, PhD, Ravi Vij, MD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 303.

https://doi.org/10.1182/blood.V114.22.303.303

Published: 2009

Journal Articles

Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM).

Ruben Niesvizky, MD, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., William Bensinger, MD, Melissa Alsina, MD, Nashat Gabrail, MD, Andres Gutierrez, MD, Lori Kunkel, MD, Michael Kauffman, MD, PhD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 304.

https://doi.org/10.1182/blood.V114.22.304.304

Published: 2009

Journal Articles

Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Studyof Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)

Sundar Jagannath, MD, Ravi Vij, MD, A. Keith Stewart, MBChB, George Somlo, MD, Andrzej Jakubowiak, MD, PhD, Tony Reiman, MD, Suzanne Trudel, MD, Jessica Taylor, BA, Diana Fuhrman, BSN, Scott Cruickshank, MS, Richard Schwartz, MD, Lori Kunkel, MD, David Siegel, MD, PhD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2008) 112 (11): 864.

https://doi.org/10.1182/blood.V112.11.864.864

Published: 2008

Journal Articles

Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)

Ravi Vij, MD, Michael Wang, MD, Robert Orlowski, MD, PhD, A. Keith Stewart, MBChB, Sundar Jagannath, MD, Vishal Kukreti, MD, FRCPC, Jessica Taylor, BA, Diana Fuhrman, BSN, Scott Cruickshank, MS, Richard Schwartz, MD, Lori Kunkel, MD, David Siegel, MD, PhD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2008) 112 (11): 865.

https://doi.org/10.1182/blood.V112.11.865.865

Published: 2008

Journal Articles

Safety and Antitumor Efficacy of the Proteasome Inhibitor Carfilzomib (PR-171) Dosed for Five Consecutive Days in Hematologic Malignancies: Phase 1 Results.

Robert Z. Orlowski, MD, PhD, Keith Stewart, MD, Marcy Vallone, Chris Molineaux, Lori Kunkel, MD, John Gericitano, MD, Owen A. O’Connor, MD

Blood (2007) 110 (11): 409.

https://doi.org/10.1182/blood.V110.11.409.409

Published: 2007

Journal Articles

Phase 1 Single Agent Antitumor Activity of Twice Weekly Consecutive Day Dosing of the Proteasome Inhibitor Carfilzomib (PR-171) in Hematologic Malignancies.

Melissa Alsina, MD, Suzanne Trudel, MD, Marcy Vallone, Christopher Molineaux, Lori Kunkel, MD, Andre Goy, MD

Blood (2007) 110 (11): 411.

https://doi.org/10.1182/blood.V110.11.411.411

Published: 2007

NARROW

The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma

Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up

Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

A Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma: Updated Efficacy and Tolerability From the Completed 20/56mg/m 2 Expansion Cohort of PX-171-007

Novel Protein Agonist of Thrombopoiesis Acts Via a Physiocrine Pathway Distinct From That of Thrombopoietin

Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM).

Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Studyof Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)

Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)

Safety and Antitumor Efficacy of the Proteasome Inhibitor Carfilzomib (PR-171) Dosed for Five Consecutive Days in Hematologic Malignancies: Phase 1 Results.

Phase 1 Single Agent Antitumor Activity of Twice Weekly Consecutive Day Dosing of the Proteasome Inhibitor Carfilzomib (PR-171) in Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only